NDA 021077 · Glaxo Grp LTD
Advair Diskus 500/50
Fluticasone Propionate, Salmeterol Xinafoate · Inhalation
Last checked: Nov 20, 2026Latest source record: Jan 7, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2000
Aug 24, 2000
Approved uses
7
Original approval plus efficacy supplements
Registered trials
738
240 Phase 3, 19 recruiting
FAERS reports
37,187
15,488 serious, 1,918 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 6, 2026.
Fluticasone Propionate/Salmeterol DISKUS is a combination product containing a corticosteroid and a long-acting beta 2 -adrenergic agonist (LABA) indicated for: • Twice-daily treatment of asthma in patients aged 4 years and older. ( 1.1 ) • Maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD). ( 1.2 ) Important limitation of use: Not indicated for relief of acute bronchospasm. ( 1.1 , 1.2 ) 1.1 Treatment of Asthma Fluticasone Propionate/Salmeterol DISKUS is indicated for the twice-daily treatment of asthma in patients aged 4 years and older. Fluticasone Propionate/Salmeterol DISKUS should be used for patients not adequately controlled on a long-term asthma control medication such as an inhaled corticosteroid (ICS) or whose disease warrants initiation of treatment with both an ICS and long-acting beta 2 -adrenergic agonist (LABA). Important Limitation of Use Fluticasone Propionate/Salmeterol DISKUS is NOT indicated for the relief of acute bronchospasm. 1.2 Maintenance Treatment of Chronic Obstructive Pulmonary Disease Fluticasone Propionate/Salmeterol DISKUS inhalation powder 250/50 mcg is indicated for the twice-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Fluticasone Propionate/Salmeterol DISKUS inhalation powder 250/50 mcg is also indicated to reduce exacerbations of COPD in patients with a history of exacerbations. Fluticasone Propionate/Salmeterol DISKUS inhalation powder 250/50 mcg twice daily is the only approved dosage for the treatment of COPD because an efficacy advantage of the higher strength Fluticasone Propionate/Salmeterol DISKUS inhalation powder 500/50 mcg...
Mechanism: Fluticasone Propionate/Salmeterol DISKUS Fluticasone Propionate/Salmeterol DISKUS contains both fluticasone propionate and salmeterol. The mechanisms of action described below for the individual components apply to Fluticasone Propionate/Salmeterol DISKUS. These drugs represent 2 different classes of medications (a synthetic corticosteroid and a LABA) that have different effects on clinical, physiologic, and inflammatory indices. Fluticasone Propionate Fluticasone propionate is a synthetic trifluorinated corticosteroid with anti-inflammatory activity. Fluticasone propionate has been shown in...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 20, 2017 Supplement 56 · Efficacy LabelLetterReview
- Dec 20, 2017 Supplement 57 · Efficacy LabelLetterReview
- Mar 31, 2009 Supplement 36 · Efficacy Letter
- Apr 30, 2008 Supplement 29 · Efficacy Summary ReviewLabelLetter
- Apr 21, 2004 Supplement 17 · Efficacy ReviewLetterLabel
- Nov 17, 2003 Supplement 3 · Efficacy ReviewLetterLabel
- Aug 24, 2000 Original approval · Type 4 - New Combination ReviewOther Important Information from FDA
3 products under this application
- ADVAIR DISKUS 500/50 · FLUTICASONE PROPIONATE 0.5MG/INH; SALMETEROL XINAFOATE EQ 0.05MG BASE/INH · POWDER, INHALATION · Prescription · TE AB
- ADVAIR DISKUS 100/50 · FLUTICASONE PROPIONATE 0.1MG/INH; SALMETEROL XINAFOATE EQ 0.05MG BASE/INH · POWDER, INHALATION · Prescription · TE AB
- ADVAIR DISKUS 250/50 · FLUTICASONE PROPIONATE 0.25MG/INH; SALMETEROL XINAFOATE EQ 0.05MG BASE/INH · POWDER, INHALATION · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Fluticasone Propionate" as an intervention, any sponsor and status, largest first.
- Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary DiseasePivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT01313676 · 16,568 participants · Start Jan 25, 2011 · Primary completion Jul 15, 2015
Drug: fluticasone furoate/vilanterol; fluticasone furoate and 1 more · For: Pulmonary Disease, Chronic Obstructive
Sites: Andalusia, Alabama; Athens, Alabama; Birmingham, Alabama · 1,611 sites in all
GlaxoSmithKlineGSK (GSK)
NCT01475721 · 11,751 participants · Start Nov 18, 2011 · Primary completion Jun 23, 2015
Drug: ADVAIR 100/50mcg; ADVAIR 250/50mcg and 4 more · For: Asthma
Sites: Athens, Alabama; Birmingham, Alabama; Florence, Alabama · 808 sites in all
- ACTIV-6: COVID-19 Study of Repurposed MedicationsPivotal-lookingCompleted
Susanna Naggie, MDAcademic, hospital or other
NCT04885530 · 10,956 participants · Start Jun 8, 2021 · Primary completion Apr 29, 2024
Drug: Ivermectin; Fluvoxamine and 3 more · For: Covid19
Sites: Chandler, Arizona; Gilbert, Arizona; Mesa, Arizona · 110 sites in all
GlaxoSmithKlineGSK (GSK)
NCT02164513 · 10,355 participants · Start Jun 30, 2014 · Primary completion Jul 17, 2017
Drug: fluticasone furoate (FF); vilanterol (VI) and 1 more · For: Pulmonary Disease, Chronic Obstructive
Sites: Athens, Alabama; Birmingham, Alabama; Florence, Alabama · 998 sites in all
- 6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years OldPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT01462344 · 6,250 participants · Start Nov 17, 2011 · Primary completion Nov 1, 2015
Drug: ADVAIR 100/50mcg; ADVAIR 250/50mcg and 2 more · For: Asthma
Sites: Birmingham, Alabama; Mobile, Alabama; Montgomery, Alabama · 530 sites in all
- Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD)Pivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT00268216 · 6,228 participants · Start Sep 2000 · Primary completion Nov 2005
Drug: Salmeterol 50mcg/ Fluticasone Propionate 500mcg · For: Pulmonary Disease, Chronic Obstructive
Sites: Birmingham, Alabama; Jasper, Alabama; Mobile, Alabama · 459 sites in all
- An Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in AsthmaPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT01706198 · 4,233 participants · Start Nov 1, 2012 · Primary completion Dec 1, 2016
Drug: fluticasone furoate + vilanterol; inhaled corticosteroid with or without a long acting beta2-agonist · For: Asthma
Sites: Altrincham, United Kingdom; Bowdon, United Kingdom; Cheadle, United Kingdom · 180 sites in all
- QVA vs. Salmeterol/Fluticasone, 52-week Exacerbation Study, FLAME (EFfect of Indacaterol Glycopyronium Vs Fluticasone Salmeterol on COPD Exacerbations)Pivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT01782326 · 3,362 participants · Start Jul 2013 · Primary completion Sep 2015
Drug: QVA149; Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS) · For: Chronic Obstructive Pulmonary Disease (COPD)
Sites: Ciudad de Buenos Aires, Argentina; Buenos Aires, Argentina; Caba, Argentina · 499 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dyspnoea5,839
- drug ineffective4,379
- product quality issue2,508
- cough2,235
- product dose omission issue2,116
- pneumonia2,059
- drug dose omission1,996
- asthma1,915
- malaise1,509
- wrong technique in device usage process1,483
- device use error1,445
- chronic obstructive pulmonary disease1,308
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 163 |
| 2005 | 79 |
| 2006 | 13 |
| 2007 | 15 |
| 2008 | 16 |
| 2009 | 34 |
| 2010 | 328 |
| 2011 | 624 |
| 2012 | 1,675 |
| 2013 | 4,671 |
| 2014 | 3,787 |
| 2015 | 5,405 |
| 2016 | 3,618 |
| 2017 | 3,249 |
| 2018 | 3,280 |
| 2019 | 2,604 |
| 2020 | 1,753 |
| 2021 | 1,204 |
| 2022 | 1,130 |
| 2023 | 936 |
| 2024 | 1,089 |
| 2025 | 586 |
| 2026 | 925 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Intranasal antihistamines and corticosteroids in allergic rhinitis: A systematic review and meta-analysis.
Sousa-Pinto B, Vieira RJ, Brozek J, et al. · J Allergy Clin Immunol 2024 · Systematic Review, Meta-Analysis
- Oral steroid-sparing effect of high-dose inhaled corticosteroids in asthma.
Maijers I, Kearns N, Harper J, et al. · Eur Respir J 2020 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Fluticasone Propionate Orally Disintegrating Tablet (APT-1011) for Eosinophilic Esophagitis: Randomized Controlled Trial.
Dellon ES, Lucendo AJ, Schlag C, et al. · Clin Gastroenterol Hepatol 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Risk of Pneumonia with Different Inhaled Corticosteroids in COPD Patients: A Meta-Analysis.
Zhang Q, Li S, Zhou W, et al. · COPD 2020 · Meta-Analysis, Systematic Review
- Efficacy of MP-AzeFlu in children with seasonal allergic rhinitis: Importance of paediatric symptom assessment.
Berger W, Meltzer EO, Amar N, et al. · Pediatr Allergy Immunol 2016 · Randomized Controlled Trial
- Comparisons of Efficacy and Safety between Triple (Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting Beta-Agonist) Therapies in Chronic Obstructive Pulmonary Disease: Systematic Review and Bayesian Network Meta-Analysis.
Lee HW, Kim HJ, Jang EJ, et al. · Respiration 2021 · Comparative Study, Systematic Review
Sponsor: GSK · Also marketed as Advair Diskus 100/50, Advair Diskus 250/50
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.